Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial

被引：0
|
作者：
Shen, Yuanming
Kong, Beihua
Xia, Bairong
Wang, Fei
Yin, Rutie
Li, Qingshui
Yue, Ying
Kang, Shan
He, Liping
Wang, Ke
Meng, Yuanguang
Wang, Shixuan
Qu, Pengpeng
Huang, Xianghua
Guo, Ruixia
Yan, Ping
Pan, Mei
Lou, Ge
Cheng, Wenjun
Xie, Xing
机构：
[1] Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[3] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
[4] Shandong Prov Hosp, Jinan, Peoples R China
[5] Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China
[6] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[7] Jilin Univ, Affiliated Hosp 1, Changchun, Peoples R China
[8] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[9] Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China
[10] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Guizhou, Peoples R China
[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[12] Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China
[13] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[14] Tianjin Cent Hosp Gynecol & Obstet, Tianjin, Peoples R China
[15] Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China
[16] Zhengzhou Univ, Affiliated Hosital 1, Zhengzhou, Peoples R China
[17] Hebei Gen Hosp, Shijiazhuang, Hebei, Peoples R China
[18] Maternal & Child Hlth Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China
[19] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[20] Jiangsu Prov Hosp, Nanjing, Peoples R China
[21] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5556
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer.
    Blank, SV
    Curtin, JP
    Goldman, NA
    Fusco, E
    Lesko, Z
    Hochster, H
    Runowicz, CD
    Wadler, S
    Muggia, FM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 467S - 467S
  • [22] A phase II study of carboplatin and doxorubicin as the first-line treatment of ovarian cancer
    Tjuiandin, S.
    Chitia, L.
    Tryakin, A.
    Stenina, M.
    Panichenko, I.
    Zhordania, K.
    Garin, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 130 - 130
  • [23] A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Dimitrios Bafaloukos
    Helena Linardou
    Gerasimos Aravantinos
    Christos Papadimitriou
    Aristotelis Bamias
    George Fountzilas
    Haralabos P Kalofonos
    Paris Kosmidis
    Eleni Timotheadou
    Thomas Makatsoris
    Epaminondas Samantas
    Evangelos Briasoulis
    Christos Christodoulou
    Pavlos Papakostas
    Dimitrios Pectasides
    Athanasios M Dimopoulos
    BMC Medicine, 8
  • [24] A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Bafaloukos, Dimitrios
    Linardou, Helena
    Aravantinos, Gerasimos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Fountzilas, George
    Kalofonos, Haralabos P.
    Kosmidis, Paris
    Timotheadou, Eleni
    Makatsoris, Thomas
    Samantas, Epaminondas
    Briasoulis, Evangelos
    Christodoulou, Christos
    Papakostas, Pavlos
    Pectasides, Dimitrios
    Dimopoulos, Athanasios M.
    BMC MEDICINE, 2010, 8
  • [25] Patients with carboplatin, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer
    Kristensen, GB
    Havsten, H
    Kaern, J
    Tropé, C
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 96 - 96
  • [26] First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients
    Romanini, A
    Tanganelli, L
    Carnino, F
    Fanucchi, A
    Lionetto, R
    Pastorino, S
    Cosio, S
    Gadducci, A
    Conte, PF
    GYNECOLOGIC ONCOLOGY, 2003, 89 (03) : 354 - 359
  • [27] Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer
    Kotani, N.
    Katsumata, N.
    Yonemori, K.
    Hirakawa, A.
    Yamamoto, H.
    Ono, M.
    Hirata, T.
    Yunokawa, M.
    Kouno, T.
    Shimizu, C.
    Tamura, K.
    Fujiwara, Y.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S40 - S40
  • [28] An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer
    Spigel, David R.
    Luft, Alexander
    Depenbrock, Henrik
    Ramlau, Rodryg
    Khalil, Mazen
    Kim, Joo-Hang
    Mayo, Carlos
    Chao, Grace Yi
    Obasaju, Coleman
    Natale, Ronald
    CLINICAL LUNG CANCER, 2017, 18 (05) : 480 - 488
  • [29] Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial (vol 4, pg 135, 2024)
    Li, Rong
    Zhang, Hongping
    Li, Qingshui
    Yuan, Guangwen
    Zhou, Yanjie
    Yin, Rutie
    Wang, He
    Wang, Chunyan
    Huang, Yi
    Wang, Wei
    Yan, Xiaojian
    Wu, Lingying
    Zhou, Qi
    JOURNAL OF THE NATIONAL CANCER CENTER, 2025, 5 (01): : 93 - 93
  • [30] Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials
    Shi, S-Q
    Jiang, F-F
    Hong, T.
    Zhuang, Y.
    Chen, L.
    Huang, X-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (06) : 2911 - 2927
12345